↓ Skip to main content

Involvement of soluble scavenger receptor A in suppression of T cell activation in patients with chronic hepatitis B

Overview of attention for article published in BMC Immunology, May 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Involvement of soluble scavenger receptor A in suppression of T cell activation in patients with chronic hepatitis B
Published in
BMC Immunology, May 2015
DOI 10.1186/s12865-015-0088-x
Pubmed ID
Authors

Ying Chen, Zuxiong Huang, Di Ma, Liqian Chen, Qintao Lai, Xuan Huang, Jia Zhou, Xiaoyong Zhang, Qiang Ma, Zhengliang Chen, Daming Zuo

Abstract

Scavenger receptor A (SRA) is expressed predominantly in phagocytic cells playing an essential role in the host immune defense against invading microorganisms. Our previous study reported the presence of SRA in a soluble form in patients with infection of hepatitis B viruses (HBV). However, the association of soluble SRA with stages of HBV infection and the immune response induced by HBV is not fully determined. In this study, we detected soluble SRA in serum from 29 chronic hepatitis B (CHB) patients, 28 chronic HBV carriers in the immune tolerant (IT) stage, 33 in the HBeAg-negative inactive carrier (IC) stage, and 22 healthy controls (HCs), respectively. We further analyzed the correlation of detected soluble SRA to inflammation and serum viral load. In addition, we investigated the regulatory role of soluble SRA in T cell activation, especially in CD8(+) T cell response to HBV peptide. We demonstrated that Median levels of serum soluble SRA in CHB and IT patients were significantly higher than those of IC patients and HCs. Additionally, the concentrations of soluble SRA were negatively correlated with alanine transaminase levels in CHB patients. We also found that serum concentration of SRA was decreased during telbivudine treatment. Expressed SRA extracellular domain suppressed HBV core peptide-stimulated interferon-γ and tumor necrosis factor-α production in CD8(+) T cells, and it bound to T cells in a higher frequency in CHB patients than in HCs. Furthermore, we observed that naïve human T cells stimulated by anti-CD3 and CD28 antibodies in the presence of the recombinant SRA protein had reduced activation and proliferation. In summary, we determined the level of soluble SRA in different stages of CHB patients. SRA might inhibit T cell proliferation and activation as a soluble form. These results not only revealed a previously unknown feature of soluble SRA in CHB patients but also provided broad understanding of SRA in T cell activation.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 17%
Student > Bachelor 4 17%
Student > Postgraduate 4 17%
Researcher 2 8%
Student > Doctoral Student 1 4%
Other 4 17%
Unknown 5 21%
Readers by discipline Count As %
Medicine and Dentistry 8 33%
Agricultural and Biological Sciences 4 17%
Immunology and Microbiology 2 8%
Computer Science 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Other 2 8%
Unknown 6 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 July 2021.
All research outputs
#7,500,672
of 23,577,654 outputs
Outputs from BMC Immunology
#136
of 592 outputs
Outputs of similar age
#87,725
of 266,741 outputs
Outputs of similar age from BMC Immunology
#5
of 16 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 592 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,741 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.